Back to top
more

Allergan plc (AGN)

(Delayed Data from NYSE)

$145.81 USD

145.81
1,518,334

+1.56 (1.08%)

Updated May 3, 2019 04:01 PM ET

After-Market: $145.88 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

WIll Allergan (AGN) Beat Estimates This Earnings Season?

by Zacks Equity Research

Allergan's (AGN) key products like Botox are likely to have provided top-line support in Q3 as loss of exclusivity of several products hurts sales.

Is a Beat in the Cards for Mallinckrodt (MNK) in Q3 Earnings?

by Zacks Equity Research

Investors are looking forward to the performance of Specialty Brands and other pipeline updates, when Mallinckrodt (MNK) reports Q3 results.

Ironwood (IRWD) Beats on Q3 Earnings & Revenues, Ups '19 View

by Zacks Equity Research

Ironwood (IRWD) witnesses strong demand for Linzess in the third quarter as well.

Is a Beat in the Cards for Regeneron (REGN) Q3 Earnings?

by Zacks Equity Research

Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates, when Regeneron (REGN) reports third-quarter 2019 results.

Mylan (MYL) to Report Q3 Earnings: What's in the Offing?

by Zacks Equity Research

Investors will look forward to regular top and bottom-line numbers, when Mylan (MYL) reports Q3 results along with updates on merger with Upjohn.

Allergan (AGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

by Zacks Equity Research

Allergan (AGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What's in the Cards for AbbVie (ABBV) This Earnings Season?

by Zacks Equity Research

AbbVie's (ABBV) Q3 sales may have been weighed down by biosimilar competition for Humira in international markets. However, strong growth of oncology drugs might have offset impact of Humira's international sales erosion.

Will Allergan (AGN) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Allergan (AGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

J&J (JNJ) Recalls Baby Powder Batch as FDA Finds Asbestos

by Zacks Equity Research

J&J (JNJ) voluntarily recalls one lot of its baby powders, which is the subject of numerous lawsuits claiming that its talc-based products contain asbestos that causes cancer.

    Kinjel Shah headshot

    Pharma Stock Roundup: JNJ's Q3 Earnings, RHHBY's Sales, FDA Nod to Lilly's Reyvow

    by Kinjel Shah

    FDA approves Lilly's (LLY) lasmiditan oral tablets to treat acute migraine. J&J (JNJ) beats earnings and sales estimates in Q3

    Editas Inks Deal for Gene Editing Neurological Disease Drugs

    by Zacks Equity Research

    Editas (EDIT) and privately held Asklepios BioPharmaceutical will collaborate on exploring in vivo delivery of genome editing medicines to treat neurological diseases.

    Kinjel Shah headshot

    Allergan (AGN) Shareholders Approve Acquisition by AbbVie

    by Kinjel Shah

    Allergan's (AGN) shareholders give green signal to its pending merger with AbbVie for a transaction value of nearly $63 billion.

    Christopher Vargas headshot

    Johnson & Johnson's (JNJ) Legal Problems Continue to Worry Investors

    by Christopher Vargas

    Johnson & Johnson (JNJ) is set to report their third quarter results as pending lawsuits loom over the company.

    Aclaris Divests Rhofade to EPI Health for $55M, Shares Up

    by Zacks Equity Research

    Aclaris (ACRS) divests worldwide rights to its rosacea drug, Rhofade, to privately-held EPI Health as part of its restructuring program.

    Ekta Bagri headshot

    Wet AMD Space in Focus: New Drug Approvals & Key Advancements

    by Ekta Bagri

    The FDA approval of Novartis' Beovu for wet AMD brings this space to focus. Let us assess the recent key developments in the area.

    J&J Settles Ahead of Multi-District Opioid Trial, Stock Up

    by Zacks Equity Research

    J&J (JNJ) reaches settlement agreement with Cuyahoga and Summit counties in Ohio concerning the lawsuits pending in MDL.

    Allergan (AGN) Stock Moves -1.09%: What You Should Know

    by Zacks Equity Research

    In the latest trading session, Allergan (AGN) closed at $166.46, marking a -1.09% move from the previous day.

    IntelGenx (IGXT) Resubmits NDA for Migraine Candidate to FDA

    by Zacks Equity Research

    IntelGenx Corp. (IGXT) resubmits NDA for Rizaport VersaFilm for the treatment of acute migraines to the FDA.

    Allergan (AGN) Stock Moves -0.1%: What You Should Know

    by Zacks Equity Research

    In the latest trading session, Allergan (AGN) closed at $166.69, marking a -0.1% move from the previous day.

    The Zacks Analyst Blog Highlights: Bristol-Myers, Lockheed, Alphabet, Allergan and Kinder Morgan

    by Zacks Equity Research

    The Zacks Analyst Blog Highlights: Bristol-Myers, Lockheed, Alphabet, Allergan and Kinder Morgan

    FDA Warns About Safety of Breast Implant: 3 Stocks at Risk (Revised)

    by Zacks Equity Research

    As breast implant-related health hazards surface, a few manufacturing companies might bear a brunt.

    Mark Vickery headshot

    Top Analyst Reports for Bristol-Myers Squibb, Lockheed Martin & Alphabet

    by Mark Vickery

    Today's Research Daily features new research reports on 16 major stocks, including Bristol-Myers Squibb (BMY), Lockheed Martin (LMT) and Alphabet (GOOGL).

    Ironwood Amends Linzess Agreement with AstraZeneca in China

    by Zacks Equity Research

    Ironwood (IRWD) announces amendment in collaboration agreement with AstraZeneca, granting the latter exclusive rights to develop, manufacture and commercialize Linzess in China.

    Sreyoshi Mukherjee headshot

    FDA Warns About Safety of Breast Implant: 3 Stocks at Risk

    by Sreyoshi Mukherjee

    As breast implant-related health hazards surface, a few manufacturing companies might bear a brunt.

    Allergan (AGN) Dips More Than Broader Markets: What You Should Know

    by Zacks Equity Research

    Allergan (AGN) closed at $165.56 in the latest trading session, marking a -0.35% move from the prior day.